CASE REPORT

A rare case of urinary bladder paraganglioma documented by $^{18}$F-FDG PET-CT: Clinical and imaging features

Azzam Abdalla Ibrahim, Steven Van Schandevyl, Peter Smeets, Ingeborg Goethals

ABSTRACT

Paragangliomas are extra-adrenal neural crest-derived neoplasms. Hybrid imaging allows for localization, preoperative planning and whole-body assessment. A rare case of urinary bladder paraganglioma is presented. In addition, in this case report, we highlight the selection of the appropriate radioactive tracer in the light of mutations.

Keywords: $^{18}$F-FDG PET-CT, Radionuclide imaging, Somatostatin receptor, Vesicular paraganglioma

INTRODUCTION

Catecholamines producing neuroendocrine tumors (NETs), pheochromocytomas, and paragangliomas (PPGLs) are rare and originate from adrenal medulla chromaffin cells (pheochromocytoma) or from neural crest-derived paraganglion cells situated in the region of the autonomic nervous system ganglia and accompanying nerves (paragangliomas).

The histology of paragangliomas is similar to that of pheochromocytomas, however, there is a higher tendency to metastasizing compared to pheochromocytoma. Increased levels of catecholamines in functional tumors account for the characteristic clinical manifestations, particularly elevated blood pressure, headache, palpitations, and diaphoresis.

The current WHO classification of endocrine tumors classifies paragangliomas in two categories: (1) head and neck paraganglioma and (2) sympathetic paraganglioma [1] (see also Table 1).

Paragangliomas occur in patients with a wide age range and there is a female predilection. One-third of paragangliomas are estimated to be hereditary with a higher prevalence of mutations in young patients. In general, PPGLs are divided into four molecularly defined subgroups: (1) the kinase signaling subtype, (2) the Wnt-altered subtype, (3) the cortical admixture subtype, and (4) the pseudohypoxia subtype. The pseudohypoxia subtype further comprises two main subgroups: the tricarboxylic acid cycle (TCA)-related PPGLs, in which mainly the succinate dehydrogenase subunits are involved/affected, and the von Hippel–Lindau (VHL)/endothelial PAS domain-containing protein 1 (EPAS-1)-related PPGLs [2].

Succinate dehydrogenase mutations (SDH) or (SDHx) account for 20% of all PPGLs. There are five subtypes: succinate dehydrogenase subunit A (SDHA), B (SDHB), C (SDHC), D (SDHD), and AF2 (SDHAF2), of these SDHD and SDHB are the most common (60% of the cases).

Succinate dehydrogenase subunit B (SDHB) mutations (10% of all PPGLs) are correlated with an increased malignant transformation (31–71%) and retroperitoneal localization [3]. Other solid tumors such as gastrointestinal stromal tumors, pituitary adenomas,
and clear cell renal cell carcinomas have been associated with these familial PPGL syndromes [3].

**CASE REPORT**

A 21-year-old man presented to the emergency room with increasing thunderclap headaches, palpitations, sweating, pallor, and anxiety after micturition. The symptoms were present for two months. Clinical examination was negative. The differential diagnosis may include (intermittent) cerebral/subarachnoid hemorrhage, due to primary or secondary hypertension, the latter related to the use of medications or illicit drugs that may increase catecholamine and metanephrine blood levels. Also psychiatric disorders such as alcohol withdrawal syndrome or anxiety disorders with panic attacks must be considered. However, when the above-mentioned typical symptoms occur during/shortly after micturition, the diagnosis of a urinary bladder paraganglioma is preferred. This was further investigated performing the following examinations:

Laboratory tests which showed a markedly increased urinary noradrenalin of 414 mcg/24 hours (normal range, 8–100 mcg/24 hours) and plasma normetanephrine of 5540 pmol/L (normal range, 48–495 pmol/L).

Even though the diagnosis of urinary bladder paraganglioma was highly probable, ¹²³I-metaiodobenzylguanidine (MIBG) and ¹¹¹In-pentetreotide scintigraphy (single-photon emission computerized tomography or SPECT) were negative/normal. Adrenal magnetic resonance imaging (MRI), to exclude a pheochromocytoma, was also negative. On the other hand, on ultrasound, cystoscopy, and ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) scan a bladder mass was seen. On PET-CT scan, the mass (30 × 20 mm, Figures 1 and 2) was intensely FDG–avid and located in the left upper wall of the bladder (Figures 1 and 2). On computed tomography (CT), the detrusor muscle appeared invaded by a heterogeneously contrast-enhancing soft-tissue mass, indicative of a richly vascularized tumor (Figure 2).

The mass was removed applying minimally invasive, robot-assisted laparoscopic surgery without opening of the bladder wall. Pathology confirmed complete resection of a vesicular paraganglioma with the typically light-microscopic appearance of a paraganglioma: a nesting pattern of epitheloid cells separated by discrete fibrovascular septa (Zellballen). Immunohistochemical staining for chromogranin, synaptophysin, neuron-specific enolase (NSE), and sustentacular cells (S-100) was positive. Additional molecular diagnostics revealed a SDHB mutation (autosomal dominant inheritance). Hence, genetic testing was recommended for (a) symptomatic first-degree relatives.

Follow-up ¹⁸F-FDG PET-CT at 1 year after surgery was unremarkable. Also, a repeat 3-year ⁶⁸Ga-DOTA-NOC PET-CT was negative.

**Table 1: Paraganglioma types**

|                          | Head and neck paraganglioma | Sympathetic paraganglioma |
|--------------------------|-----------------------------|---------------------------|
| **Type of ganglia**      | Parasympathetic             | Sympathetic               |
| **Functionality**        | Generally nonfunctioning.   | Generally functioning.    |
| **Usual locations**      | Carotid body, jugulotympanic (middle ear), vagal paraganglioma and laryngeal paraganglioma. | Infra- and supradiaphragmatic (85%): The retroperitoneum around the adrenal/renal area, around the organ of Zuckerkandl or in the urinary bladder. |
| **Metastasis risk**      | Low risk (low than 5%).     | High risk: Could be up to 50% with SDHB mutation. |

**Figure 1:** ¹⁸F-FDG PET-CT maximum intensity projection (MIP) anterior and lateral images showing an intensely FDG-avid, nodular lesion (arrowheads).
provides a better image quality, has a lower radiation benefit from (radionuclide) therapy.

It is specific for PPGL, may visualize these tumors in body assessment/screening than anatomical imaging.

Diagnosis is further confirmed by an elevated 24-hour normetanephrine level, ultrasound, and cystoscopy. It is noteworthy that the bladder is an unusual location during/shortly after micturition. As such, the typical symptoms in our case are due to the release of massive catecholamines in the blood stream, which are caused by compression of the tumor by a contracting detrusor muscle during micturition. [4]

Diagnosis is straightforward. Imaging, and in particular hybrid PET-CT imaging, is performed to rule out multiple tumors and distant metastases [5].

On CT, paragangliomas are typically observed as heterogeneous soft tissue masses (attenuation greater than 10 Hounsfield units) with intense contrast enhancement, reflecting the high vascularization. An intermediate to high signal intensity is seen on T2-weighted MRI, with post-gadolinium enhancement on T1-weighted MRI [6, 7].

Radioisotope imaging is more sensitive for whole-body assessment/screening than anatomical imaging. It is specific for PPGL, may visualize these tumors in unusual locations, and can identify patients who may benefit from (radionuclide) therapy.

On scintigraphy, metaiodobenzylguanidine (MIBG) which is radiolabelled with 123I or 131I acts as a norepinephrine analog which is internalized by the sympathetic paraganglioma cells. 123I MIBG scintigraphy is preferred over 131I MIBG scintigraphy because it provides a better image quality, has a lower radiation burden which allows higher permissible administered activity and as a result a higher count rate. Moreover, 18F-FDOPA is technically easier to perform with less time between injection and imaging, 24 hours for 123I MIBG compared with 48–72 h for 131I MIBG scintigraphy. Pentetreoctide is a diethylenetriaminepentaacetic (DTPA) conjugate of octreotide and a long-acting somatostatin analogue (SSA). [123In] DTPA-pentetreoctide specifically binds to the somatostatin receptors (SSTRs), particularly the subtypes 2 and 5, that are overexpressed on the cell membranes. Therefore, both tracers are suited for imaging PGGL. However, the sensitivity of 123I-MIBG or 11In-pentetreoctide scintigraphy is lower than that of PET-CT, mainly because of an inferior SPECT resolution compared to PET.

The choice of the most appropriate PET radiotracer for imaging PGGLs can be challenging. 18F-fluoro-l-dopa (FDOPA) (PET-CT) is taken up by the tumor cells of PGGLs. In the cell, 18F-FDOPA is decarboxylated, converted into [18F] fluorodopamine ([18F] FDA) by L-aromatic amino acid decarboxylase (AADC) and stored in the neurosecretory vesicles of the catecholamine-producing cells [7]. This means that there is selective tracer accumulation in the tumor cells, which enhances the contrast between a low background and the tumor. Moreover, the resolution of PET is superior to that of SPECT and the high three-dimensional acquisition yield renders excellent quality PET whole-body images that significantly improve image interpretation in comparison with SPECT. It is also worth mentioning that certain medications do not need to be discontinued which is the case for 123/131 I MIBG imaging. All of the above make 18F-FDOPA PET-CT the first choice for imaging pheochromocytomas and head and neck paragangliomas with a sensitivity of >90% for head and neck PGGL and almost 100% for pheochromocytoma, the latter due to the limited uptake of the tracer by normal adrenal glands [7, 8]. However, sensitivity in retroperitoneal paragangliomas may be decreased by the physiological uptake in the pancreas [9]. Furthermore 18F-FDOPA PET-CT sensitivity in PGGLs related to SDHx mutations is lower than in non-SDHx mutated PGGLs [7, 9–11].

The PET tracer 68Ga-DOTA, which targets the SSTR2 that is most commonly overexpressed in PGGLs, may also be used. This PET tracer is also internalized into the cells. Recent studies show that 68Ga-DOTA is likely superior to other radiopharmaceuticals for patients with extra-adrenal PGGLs [7, 12]. Recently published data in patients with extra-adrenal PGGLs, 68Ga-DOTA PET-CT showed better patient-based and lesion-based detection rates than did 18F-FDOPA PET-CT (98% vs. 95% and 99% vs. 68%, respectively) [7]. Furthermore, 68Ga-DOTA PET-CT may allow optimization of targeted radionuclide therapy with 177Lu-DOTA-TATE.

As is the case for 18F-FDOPA, availability and cost of 68Ga-DOTA are often an issue. Moreover, in the United States, these tracers can only be used in the context of clinical trials [7, 12].

DISCUSSION

Based on the clinical manifestations in our case, a functional PGGL is suspected. Particularly, a functional PGGL localized in the bladder wall is highly probable because the typical symptoms such as thunderclap headaches, hypertension, and palpitations occur only during/shortly after micturition. As such, the typical symptoms in our case are due to the release of massive catecholamines in the blood stream, which are caused by compression of the tumor by a contracting detrusor muscle during micturition. [4]

Figure 2: 18F-FDG PET-CT fusion transvers image (A) and CT transvers image (B), 18F-FDG PET-CT fusion coronal image (C), CT coronal image (D), showing an intensely FDG-avid, nodular lesion (30 × 20 mm, arrowheads).
Contrarily, the wide availability and relatively low cost of $^{18}$F-FDG makes it a reasonable first choice, especially in SDHx mutated paragangliomas. The better $^{18}$F-FDG avidity in SDHx is explained by the accumulation of succinate due to blockade of the Krebs cycle, which results in what is called “pseudohypoxia.” This phenomenon results in a higher glucose uptake and consumption due to increased glycolysis despite normal oxygen supply [13]. The sensitivity is particularly high for PPGls associated with SDHB mutations (sensitivity per lesion of 83% for SDHB-positive tumors vs. 62% for SDHB-negative tumors), compared to $^{18}$F- FDOPA (sensitivity of 93% for SDHB negative vs. 20% for SDHB positive) [7, 9, 14].

Upon presentation of our patient at our hospital, $^{68}$Ga-DOTA and $^{18}$F-FDOPA PET were not available, which explains why, after a negative $^{123}$I-MIBG scintigraphy, $^{18}$F-FDG PET-CT was performed.

CONCLUSION

$^{68}$Ga-DOTA-SST analogue PET-CT and $^{18}$F-FDOPA PET-CT are considered the first choice for imaging patients with suspected paraganglioma. However, availability and cost can be problematic. $^{18}$F-FDG PET-CT is a reasonable alternative because it is widely available and relatively less costly. In addition, $^{18}$F-FDG is an appropriate PET tracer for SDHx-mutated PPGls.

REFERENCES

1. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. Lyon: IARC Press; 2017.
2. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 2017;34(2):181–93.
3. Cascón A, Remacha L, Calsina B, Robledo M. Pheochromocytomas and paragangliomas: Bypassing cellular respiration. Cancers 2019;11(5):683.
4. Reiland JA, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: A systematic review of the contemporary literature. BMC Urol 2013;13:22.
5. Antonio K, Valdez MMN, Mercado-Asis L, Taieb D, Pacak K. Pheochromocytoma/paraganglioma: Recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg 2020;9(1):105–23.
6. Canu L, Van Hemert JAW, Kerstens MN, et al. CT Characteristics of pheochromocytoma: Relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab 2019;104(2):312–8.
7. Taieb D, Hicks RJ, Hindie E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019;46(10):2112–37.
8. Taieb D, Jha A, Guerin C, et al. $^{18}$F-FDOPA PET/CT imaging of MAX-related pheochromocytoma. J Clin Endocrinol Metab 2018;103(4):1574–82.
9. Treglia G, Cocciolillo F, de Waure C, et al. Diagnostic performance of $^{18}$F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: A meta-analysis. Eur J Nucl Med Mol Imaging 2012;39(7):1144–53.
10. Taieb D, Sebag F, Barlier A, et al. $^{18}$F- FDG avidity of pheochromocytomas and paragangliomas: A new molecular imaging signature? J Nucl Med 2009;50(5):711–7.
11. Timmers HJLM, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2007;10:16.
12. Lenders JWM, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(6):1915–42.
13. Taieb D, Pacak K. New insights into the nuclear imaging phenotypes of cluster 1 pheochromocytoma and paraganglioma. Trends Endocrinol Metab 2017;28(11):807–17.
14. Timmers HJLM, Chen CC, Carraquillo JA, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) positron emission tomography. J Natl Cancer Inst 2012;104(9):700–8.

**********

Author Contributions

Azzam Abdalla Ibrahim – Conception of the work, Design of the work, Acquisition of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Steven Van Schandevel – Design of the work, Acquisition of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Peter Smeets – Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Ingeborg Goethals – Conception of the work, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published.
published. Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Guarantor of Submission**
The corresponding author is the guarantor of submission.

**Source of Support**
None.

**Consent Statement**
Written informed consent was obtained from the patient for publication of this article.

---

**Conflict of Interest**
Authors declare no conflict of interest.

**Data Availability**
All relevant data are within the paper and its Supporting Information files.

**Copyright**
© 2021 Azzam Abdalla Ibrahim et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
